VXRT News and Press, Vaxart Inc. From 06/30/22

Vaxart ( VXRT ) said on Thursday it had entered an agreement with hVIVO Services Limited, a subsidiary of London-based firm Open Orphan. Under the agreement, hVIVO will conduct a study and develop a human challenge model based on the Omicron variant of SARS-CoV-2 with...

Model will be used in Vaxart’s Phase II Omicron Challenge Trial Open Orphan subsidiary hVIVO to manufacture challenge virus and conduct characterization study SOUTH SAN FRANCISCO, Calif., June 30, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced an...

Management to discuss progress on its programs, annual stockholders’ meeting proposals Webcast to be held on June 22 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will host ...

Today, we put Vaxart in the spotlight for the first time. The company is developing several vaccine candidates targeting large potential markets via an oral pill that can be stored at room temperature. An investment analysis follows in the paragraphs below. For further detai...

Meeting adjourned to July 6, 2022 at 9:30 a.m. PT Vaxart encourages all stockholders of record on April 11, 2022 who have not yet voted to do so by 11:59 p.m. Eastern Time on July 5, 2022 SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (...

If your portfolio looks like it could use a shot in the arm lately, you're not alone. Between macroeconomic disruption and a lingering pandemic, finding sources of growth is as important as ever, and biotech stocks just might fit the bill. Novavax (NASDAQ: NVAX) and Vaxart ...

Vaxart (NASDAQ:VXRT) on Friday reported positive preliminary preclinical data that showed two of its COVID-19 vaccine candidates targeting either the SARS-CoV-2 spike (S) protein for Wuhan or S protein for Omicron protected hamsters when challenged with the Omicron BA.1 variant. The...

Results provide additional support for the cross-reactivity of Vaxart’s oral vaccine candidates SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today reported positive preliminary preclinical data demonstrating that two COVID-19 va...

Vaxart (NASDAQ:VXRT) on Thursday reported what it deemed to positive preliminary data from its phase 1b trial of its oral norovirus vaccine candidate in adults aged 55-80 years. VXRT stock +1.2% to $3.49 in premarket trading. The vaccine candidate targets the norovirus, a very conta...

Investors ought to be even more careful where they put their money in times like these. It's more important than ever to make highly selective investment decisions with a struggling stock market, challenging economic issues, and dangerous geopolitical tensions. Sure, many companies that...